Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing.
Martínez-Sánchez MV, Periago A, Legaz I, Gimeno L, Mrowiec A, Montes-Barqueros NR, Campillo JA, Bolarin JM, Bernardo MV, López-Álvarez MR, González C, García-Garay MC, Muro M, Cabañas-Perianes V, Fuster JL, García-Alonso AM, Moraleda JM, Álvarez-Lopez MR, Minguela A.
Martínez-Sánchez MV, et al. Among authors: legaz i.
Oncoimmunology. 2015 Oct 29;5(4):e1093721. doi: 10.1080/2162402X.2015.1093721. eCollection 2016 Apr.
Oncoimmunology. 2015.
PMID: 27141379
Free PMC article.